← 治験一覧に戻る
進行がんを患う日本人参加者を対象としたLY3023414の研究
基本情報
- NCT ID
- NCT02536586
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 12
- 治験依頼者名
- Eli Lilly and Company
概要
The main purpose of this study is to evaluate the tolerability of an investigational drug known as LY3023414 in Japanese participants with advanced cancer or cancer that has spread to another part(s) of the body. The study will also explore the safety of the drug. It will measure how much of the drug gets into the blood steam and how long the body takes to get rid of it. It will investigate anti-cancer activity.
対象疾患
Neoplasm
介入
LY3023414(DRUG)
依頼者（Sponsor）
日本イーライリリー株式会社(INDUSTRY)